ISIN | LU0942225912 |
---|---|
Valor Number | 21612660 |
Bloomberg Global ID | |
Fund Name | Candriam Equities L Biotechnology R-Acc |
Fund Provider |
CANDRIAM
Serenity, Bloc - B, 19-21, route d'Arlon 8009 Strassen E-Mail: CH@Candriam.com Phone: + 352 2797-1 Web: https://www.candriam.com |
Fund Provider | CANDRIAM |
Representative in Switzerland |
CACEIS (Switzerland) SA Nyon Phone: +41 22 360 94 00 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Peculiarities |
Current Price * | 258.72 USD | 31.03.2025 |
---|---|---|
Previous Price * | 264.67 USD | 28.03.2025 |
52 Week High * | 307.14 USD | 08.11.2024 |
52 Week Low * | 248.00 USD | 19.04.2024 |
NAV * | 258.72 USD | 31.03.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,358,231,399 | |
Unit/Share Assets *** | 31,783,125 | |
Trading Information SIX |
YTD Performance | -4.51% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
---|---|---|
YTD Performance (in CHF) | -6.98% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
1 month | -6.94% |
28.02.2025 - 31.03.2025
28.02.2025 31.03.2025 |
3 months | -4.51% |
31.12.2024 - 31.03.2025
31.12.2024 31.03.2025 |
6 months | -11.99% |
30.09.2024 - 31.03.2025
30.09.2024 31.03.2025 |
1 year | -1.54% |
02.04.2024 - 31.03.2025
02.04.2024 31.03.2025 |
2 years | +9.56% |
31.03.2023 - 31.03.2025
31.03.2023 31.03.2025 |
3 years | +13.42% |
31.03.2022 - 31.03.2025
31.03.2022 31.03.2025 |
5 years | +40.83% |
31.03.2020 - 31.03.2025
31.03.2020 31.03.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Gilead Sciences Inc | 7.48% | |
---|---|---|
Amgen Inc | 6.31% | |
Regeneron Pharmaceuticals Inc | 5.92% | |
Vertex Pharmaceuticals Inc | 5.83% | |
Alnylam Pharmaceuticals Inc | 3.99% | |
BioNTech SE ADR | 3.26% | |
Insmed Inc | 2.73% | |
Ascendis Pharma AS ADR | 2.52% | |
BeiGene Ltd ADR | 2.48% | |
Biomarin Pharmaceutical Inc | 2.34% | |
Last data update | 28.02.2025 |
TER *** | 1.11% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.11% |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |